Brendon Neuen
@brendonneuen
Nephrologist & Director, Kidney Trials @NthSydHealth | @NHMRC supported @GeorgeInstitute Fellow | Secretariat, SMART-C | via @BrighamWomens @Oxford_NDPH
ID:25062503
https://www.georgeinstitute.org/people/brendon-neuen 18-03-2009 12:14:59
6,6K Tweets
4,2K Followers
1,6K Following
Follow People
With FLOW trial presentation this month at #ERA24 , check out this Circulation On the Run podcast with Peder L. Myhre 🫀, Sandeep Das & me, discussing potential lifetime benefits of combination treatment with #4pillarsCKD : RASi, SGLT2i, ns-MRA & GLP-1RA
podcasts.apple.com/au/podcast/cir…
#kidneyGDMT
Nice coverage of the recent SMART-C collaborative meta-analysis in Circulation, led by Sid M. Patel Stephen Wiviott & TIMI Study Group
medicalrepublic.com.au/sglt2s-cut-car…
Next SMART-C presentation at ERA - European Renal Association: Effects of SGLT2i with & without GLP-1RA
Find out more at SMART-C.net
💊From SGLT2 inhibitors to mineralocorticoid receptor antagonists, we'll explore innovative treatments and new indications.
🎙️Join us in the 12th episode of our #ERAPodcast #APinchOfSalt 🧂with Katherine Tuttle.
🎧 Hit play now 👉 bit.ly/3SdsxU0
Great review of DUPLEX with first author Michelle Rheault and expert trialist Brendon Neuen
Great to see the rigorous study of sparsentan in FSGS, hopefully sets the stage for future efforts
podcasts.apple.com/us/podcast/fre…
A new approach to initiating guideline-directed medical therapy in patients with type 2 #diabetes & chronic #kidney disease has been proposed, with the benefits of prioritising absolute risk reduction & maximising cost effectiveness
Brendon Neuen Circulation
thelimbic.com/nephrology/how…
Super fun as always to join Freely Filtered: A NephJC Podcast - discussing all things FSGS, GFR slope / endpoint definitions, & lessons for next gen rare disease trials
Thanks Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Priya Yenebere Nayan Arora,MD Michelle Rheault for another fun episode
podcasts.apple.com/au/podcast/fre…
#nephjc
Nick Mark MD Freely Filtered: A NephJC Podcast Chapters are supported in the podcast spec, it even allows you to change the episode with each chapter, we did this for chronic v total GFR slope which was relevant for this episode and it works across platform. See how chapters are displayed in Apple Podcasts on my iPhone.
I…
Super fun as always to join Freely Filtered: A NephJC Podcast - discussing all things FSGS, GFR slope / endpoint definitions, & lessons for next gen rare disease trials
Thanks Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Priya Yenebere Nayan Arora,MD Michelle Rheault for another fun episode
podcasts.apple.com/au/podcast/fre…
#nephjc
Excited and proud to be part of the first regional World Health Summit to be held in Australia!
Looking forward to hearing some amazing talks and forging new connections to make serious headway in #healthequity in APAC and beyond.
AAMRI Public Health Australia UN Human Rights World Health Organization South-East Asia
Delighted to join the American Society of Nephrology Journals’ Editorial Board and look forward to working with Rajnish Mehrotra, Connie Rhee & all involved at these great journals to advance kidney science
An honor to present at the Global Trials Summit 2024 today with so many🌟in the field. The case for #ImplementationScience in #HF & broadly across #CKM could not be stronger - so many tools for patients & yet much more work to do. 🙏Mark Petrie Pardeep S Jhund Harriette Van Spall, MD MPH and team for the opportunity.
SGLT2 inhibitors reduce the risk of cardiovascular disease in patients with CKD. This study found SGLT2 inhibitors reduced risk of cardiovascular death, having the most pronounced effects on risk of deaths attributed to heart failure bit.ly/CJASN0470
David C Wheeler